MedPath

Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans

Recruiting
Conditions
Arteriosclerosis Obliterans
Interventions
Procedure: open bypass group
Procedure: bare metal stent group
Procedure: plain old balloon angioplasty group
Procedure: drug-coated balloon group
Procedure: directional atherectomy group
Procedure: hybrid repair group
Registration Number
NCT06485622
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Brief Summary

This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.

Detailed Description

Arteriosclerosis obliterans (ASO) is a kind of lower extremity arterial disease which occurs frequently in middle-aged and elderly people. The incidence of ASO increases with age. In patients with ASO, the build-up of fatty deposits, cholesterol, and other substances (plaques) in the arteries reduces blood flow to the extremities. This can lead to symptoms such as leg pain, cramping, and fatigue, especially during physical activity. In severe cases, it may result in pain at rest, non-healing wounds, and complications such as tissue damage or infection. Chronic wound is one of the symptoms that affect the quality of life. Therefore, wound healing is also an important index for postoperative care. However, no study has reported detailed performance data for different treatments. As an auxiliary method in clinical treatment, nutrition plays an important role in improving the clinical outcome of patients in the development and postoperative stages of the disease. The effect of nutritional risk assessment and nutritional education on postoperative symptoms of ASO has not been reported. Therefore, we plan to carry out this prospective, single-center, observational study, providing new data on the efficacy, safety and cost-effectiveness for different treatment and assistive techniques in lower extremity arterial occlusive disease.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  1. Age 18 years or older, gender is not limited.
  2. Patients diagnosed with arteriosclerosis obliterans.
  3. Rutherford stages 2-6.
  4. When there are multiple stenosis lesions, the treatment of the most severe lesion is included.
  5. Patients with at least one arterial occlusion ( iliac, femoral, popliteal, anterior tibial, posterior tibial, and/or peroneal artery) of the lower extremity were included.
Exclusion Criteria
  1. Malignant tumor
  2. Alzheimer's disease
  3. Blood disease or bleeding tendency
  4. Heart Failure Grade III ~ IV
  5. Pregnancy or lactation
  6. An above-knee-below-knee amputation has been performed
  7. Unable to accept therapeutic function tests
  8. Life expectancy is less than six months
  9. Combined with other diseases affecting walking
  10. Cardiovascular and cerebrovascular events occurred within 3 months, including non-fatal myocardial infarction, unstable angina, stable angina, non-fatal ischemic stroke and hemorrhagic stroke
  11. Patients with significant abnormal liver and renal function that the investigators judged to be clinically significant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Bypass groupopen bypass groupopen bypass group
BMS groupbare metal stent groupBMS (bare metal stent) group
POBA groupplain old balloon angioplasty groupPOBA (plain old balloon angioplasty) group
DCB groupdrug-coated balloon groupdrug-coated balloon group
DA groupdirectional atherectomy groupDA (directional atherectomy) group
HR grouphybrid repair groupHR (hybrid repair) group
Primary Outcome Measures
NameTimeMethod
All cause mortality rate1 month; 6 months; 12 months; 24 months; 36 months

Death due to any cause.

Limb salvage rate1 month; 6 months; 12 months; 24 months; 36 months

Freedom from above ankle amputation in target limb.

Primary patency rate1 month; 6 months; 12 months; 24 months; 36 months

Primary patency of target lesion is assessed by the vascular ultrasound.

Major adverse limb event (MALE) rate1 month; 6 months; 12 months; 24 months; 36 months

Major adverse limb events include anyone of the following: Amputation in target limb and major re-intervention on target limb.

Secondary Outcome Measures
NameTimeMethod
Restenosis of the target lesion1 month; 6 months; 12 months; 24 months; 36 months

A peak systolic velocity ratio of over 2.4 measured using duplex ultrasound, \>50% diameter stenosis or occlusion by follow-up angiography.

Quality-adjusted life-years (QALYs)1 month; 6 months; 12 months; 24 months; 36 months

Time is measured in years and the VascuQol (Vascular Quality-of-Life, scored on a scale from 1 to 7 by using the VascuQol-25 questionnaire) on an index scale ranging from 1 (worst possible) to 7(best possible). The total number of QALYs was calculated by multiplying the HRQoL index score (QALY weight) by the time spent in each health state. One QALY can be viewed as living for 1 year in the best possible health.

Major adverse cardiovascular events (MACE)1 month; 6 months; 12 months; 24 months; 36 months

Major adverse cardiovascular events include anyone of the following: Major amputations, myocardial infarction, ischemic stroke, arterial puncture problems requiring intervention, and acute kidney failure associated with endovascular therapy.

Survival Rate1 month; 6 months; 12 months; 24 months; 36 months

Telephone follow-up visit and/or medical chart review and/or publicly available records consultation for vital status.

Trial Locations

Locations (1)

The First Affiliated Hospital of Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath